Interstitial Pneumonitis Secondary to Trastuzumab: A Case Report and Literature Review.

Autor:	Costa R; Division of Hematology/Oncology, Feinberg School of Medicine, Chicago, Illinois, USA., Costa-Filho RB; Division of Hematology/Oncology, Feinberg School of Medicine, Chicago, Illinois, USA., Talamantes SM; Feinberg School of Medicine, Chicago, Illinois, USA., Queiroga F Jr; Division of Pulmonary Medicine, Real Hospital Portugues, Recife, Brazil., Campello EC; Division of Pulmonary Medicine, Real Hospital Portugues, Recife, Brazil., Cartaxo H; Department of Radiology, Real Hospital Portugues, Recife, Brazil., Costa RB; Instituto de Diagnostico e Tratamento Oncologico, Recife, Brazil.
Jazyk:	angličtina
Zdroj:	Case reports in oncology [Case Rep Oncol] 2017 Jun 14; Vol. 10 (2), pp. 524-530. Date of Electronic Publication: 2017 Jun 14 (Print Publication: 2017).
DOI:	10.1159/000477340
Abstrakt:	Interstitial lung disease is a rare complication of trastuzumab-based breast cancer treatment with few case reports published. Herein, we report the case of a 67-year-old female with early-stage HER2-postitive breast cancer who developed interstitial pneumonitis during cycle 5 of treatment with trastuzumab combined with carboplatin and docetaxel. After supportive care and treatment with prednisone, the patient showed rapid improvement of respiratory symptoms. Retreatment with trastuzumab as a single agent led to worsening of symptoms and required a second course of treatment with prednisone combined with cyclophosphamide, which was followed by improvement of symptoms. In conclusion, interstitial pneumonitis is a rare but life-threatening adverse event from trastuzumab breast cancer treatment.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu